PGEN vs PVLA Stock Comparison

PVLA currently leads PGEN in this stock comparison, with AIQ scores of 70 vs 55. The clearest difference is momentum.

Market data as of Nov 15, 2026 market close· AIQ score gap 15 points
PGEN
Healthcare
vs
PVLA
Healthcare
PGEN
Precigen, Inc.
Price
$4.54
Day move
-2.58%
AIQ Score
55/100
Best edge
Balanced
Sector
Healthcare
PVLA
Palvella Therapeutics, Inc.
Leads
Price
$152
Day move
-0.46%
AIQ Score
70/100
Best edge
Momentum
Sector
Healthcare

What is the main difference between PGEN and PVLA?

PVLA leads the current stock comparison as Palvella Therapeutics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Precigen, Inc. vs Palvella Therapeutics, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 63/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 8/10

PVLA leads

PVLA leads by 15 AIQ points, primarily on Momentum and Risk Resilience, and the lead has widened from 0 points over 30 sessions. Wall Street currently favors PGEN on target upside.

Stable: 3 of 5 evidence groups support PVLA, its lead is widening, and its signal state is cleanly positive.

Evidence agreement: 3 of 5Comparison trend: Strengthening
PGEN

Precigen, Inc.

AIQ Score
55/100
AIQ Edge Score
5/10
PVLA

Palvella Therapeutics, Inc.

Leads
AIQ Score
70/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors PVLA over PGEN, 70 versus 55 as of Nov 15, 2026. PVLA's advantage is driven primarily by stronger momentum and risk resilience. PVLA also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors PGEN. 3 of 5 covered evidence groups favor PVLA today, and the comparison is rated Stable on stability. PVLA lead: Strengthening — the AIQ differential moved from 0 to 15 points over 30 sessions.

Compare Precigen, Inc. and Palvella Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

PGEN
+574.0%
PVLA
+1088.5%

Price return comparison

Growth of $10,000, price only

PGEN $67,399 · PVLA $118,846

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare PGEN and PVLA against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

PGEN advantage
0
PVLA advantage
  • Momentum55 vs 84
    PVLA +29
  • Risk Resilience31 vs 47
    PVLA +16
  • Quality60 vs 65
    PVLA +5

3 of 5 evidence groups favor PVLA. PVLA’s edge is concentrated in momentum and risk resilience.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

PGEN+1 AIQ

No factor moved materially.

New signals

  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Keltner Channel Breakdown — bearish, volatility, short horizon
PVLA+2 AIQ

Largest factor move: Momentum +4

No signal started or stopped since the prior session; its 5 active signals are unchanged.

PVLA's lead widened by 1 AIQ point in the latest session.

Deeper signal detail for each name lives on its own signals page — PGEN and PVLA both carry a full feed there.

The central trade-off

PVLA (Palvella Therapeutics, Inc.): the stronger current systematic profile, led by momentum and risk resilience.

PGEN (Precigen, Inc.): the counter-case, on fundamentals, analyst expectations — but at materially higher volatility, 127% against 75.1%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

PVLA

PVLA on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

PGEN

PGEN on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

PVLA

PVLA on the Momentum factor, by 29 points.

Lower downside

PVLA

PVLA on Risk Resilience, by 16 points.

Analyst upside

PGEN

PGEN on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors PVLA, analyst targets favor PGEN. That disagreement is the most useful thing on this page.

MeasurePGENPVLANote
Implied upside to target+164.3%+55.6%PGEN has more room
Target dispersion0%+8.4%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering416Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

3 of 5 covered evidence groups favor PVLA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScorePVLA55 vs 70
FundamentalsPGENEPS growth 66.7% vs -11.8%; TTM ROE 42.7% vs -12.5%
ValuationNot coveredNot covered
TechnicalsPVLAPrice vs 50-day -32.6% vs 6.2%; vs 200-day -14% vs 16.9%
Risk ResiliencePVLARisk Resilience 31 vs 47
Analyst expectationsPGENTarget upside 164.3% vs 55.6%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PGEN and PVLA and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 15 points. (supports the conclusion holding)
  • The leader's advantage has been widening. (supports the conclusion holding)
  • The leader's signal state is cleanly positive. (supports the conclusion holding)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PVLA.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

PVLA lead: Strengthening — the AIQ differential moved from 0 to 15 points over 30 sessions.

May 27PGEN leads above the line · PVLA leads belowNov 13
Today
PVLA +15
55 vs 70
7 sessions ago
PVLA +5
62 vs 67
30 sessions ago
Level
61 vs 61
90 sessions ago
PVLA +13
58 vs 71

The lead changed hands once in this window, most recently on Oct 22 when PVLA moved ahead of PGEN.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

PGENConflicted

1 bullish / 2 bearish / 2 neutral, conflicted

Only PGEN

  • ADX Trend Strengthening — neutral, trend, medium horizon
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Keltner Channel Breakdown — bearish, volatility, short horizon
PVLA

4 bullish / 0 bearish / 1 neutral

Only PVLA

  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
  • TRIX Bullish Signal — bullish, momentum, short horizon
  • Uptrend Structure Active — bullish, trend, long horizon

Both carry 2 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode.

PGEN is conflicted, so the timing case there is weaker than the score alone suggests.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

PGENDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.58%, AIQ +1 points).

PVLADivergence

Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.46%, AIQ +2 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1PGEN closes the Momentum gap — currently 29 points behind, the largest single contributor to PVLA's edge.
  2. 2PGEN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3PVLA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

PGEN leads on balance
MetricPGENPVLA
Revenue growth (YoY)34.9%0%
EPS growth (YoY)66.7%-11.8%
Gross margin91%0%
Operating margin21.4%0%
Return on equity (TTM)42.7%-12.5%
Debt to equity1.180

Performance

PVLA leads 5 of 6 windows
MetricPGENPVLA
1 week (5 sessions)1.6%-13.3%
1 month (20 sessions)-28.9%26.7%
3 months (63 sessions)-30.7%-0.7%
6 months (126 sessions)2.7%33.5%
Year to date8.6%45.7%
1 year (252 sessions)12.9%87%

Technicals

PVLA has the stronger structure
MetricPGENPVLA
RSI (14)34.252.6
ADX (14)28.831.1
Price vs 50-day-32.6%6.2%
Price vs 200-day-14%16.9%
Volatility (1M, annualized)127%75.1%

Risk

PVLA is the more resilient
MetricPGENPVLA
Beta1.621.65
Sharpe ratio0.571.12
Sortino ratio0.871.87
Max drawdown-50.7%-31.1%
Current drawdown-47%-13.3%
Annualized volatility85.4%84.5%
Value at risk (95%)-7.2%-6.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, PGEN or PVLA?

On the Algovestiq AIQ Score, PVLA is the stronger of the two as of Nov 15, 2026, scoring 70 against PGEN's 55. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is PGEN or PVLA the better buy right now?

PVLA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 3 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor PVLA over PGEN?

The composite weights Quality, Value, Momentum and Risk Resilience. PVLA leads Momentum by 29 points; PVLA leads Risk Resilience by 16 points; PVLA leads Quality by 5 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, PGEN or PVLA?

Analyst price targets imply +164.3% upside for PGEN and +55.6% for PVLA, so the Street currently favors PGEN. That points the opposite way to the AIQ Score, which favors PVLA. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, PGEN or PVLA?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, PGEN or PVLA?

PGEN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, PGEN or PVLA?

PVLA on the Momentum factor, by 29 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, PGEN or PVLA?

PVLA is the more resilient of the two, so the other name carries the higher downside risk. PVLA on Risk Resilience, by 16 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is PGEN more profitable than PVLA?

PGEN leads on the comparable margin measures — gross margin 91% vs 0%; operating margin 21.4% vs 0%; ttm roe 42.7% vs -12.5%.

Is PVLA's lead over PGEN getting stronger or weaker?

PVLA lead: Strengthening — the AIQ differential moved from 0 to 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-10-22, when PVLA moved ahead of PGEN.

What would change the PGEN vs PVLA verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PGEN closes the Momentum gap — currently 29 points behind, the largest single contributor to PVLA's edge; PGEN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; PVLA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about PGEN and PVLA?

PGEN: 1 bullish / 2 bearish / 2 neutral, conflicted. PVLA: 4 bullish / 0 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PGEN is Golden Cross Active (bullish, long horizon). On PVLA it is Golden Cross Active (bullish, long horizon).

Compare PGEN and PVLA with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.